Focal therapy: A treatment option for localised prostate cancer?
Abstract
Keywords
Full Text:
PDFReferences
Epstein J, Walsh P, Carmichael M, Brendler C. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage t1 c) prostate cancer. JAMA 1994; 271(5): 368–74.
Lu-Yao G, Yao S. Population-based study of long-term survival in patients with clinically localised prostate cancer. The Lancet 1997; 349(9056): 906–910. doi: 10.1016/S0140-6736(96)09380-4.
Sanda M, Dunn R, Michaliski J Sandler HM, Northouse L, et al., Quality of life and satisfaction with outcome among prostate-cancer survivors. New Eng J Med 2008; 358(12): 1250–1261. doi: 10.1056/NEJMoa074311.
Eifler J, Carter H. Patient selection for active surveillance. In: Active surveillance for localized prostate cancer: A new paradigm for clinical management. L. Klotz (editor). New York: Humana Press. 2012. p. 9–21.
Karavitakis M, Winkler M, Abel PD, Hazell S, Ahmend HU. Focal therapy for prostate cancer: Opportunities and uncertainties. Discov Med 2011; 12(64): 245–255.
Mearini L, Porena M. Pros and cons of focal therapy for localised prostate cancer. Prostate Cancer 2011; 2011: 584784. doi:10.1155/2011/584784.
Heidenreich A, Bastian P, Bellmunt J Bolla M, Jonuau S, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65(1): 124–137. doi: 10.1016/j.eururo.2013.09.046.
Jácome-Pita F, Sánchez-Salas R, Barret E, Amaruch N, Gonzalez-Enguita C, et al. Focal therapy in prostate cancer: The current situation. Ecancermedicalscience, 2014; 8: 435. doi: 10.3332/ecancer.2014.435.
Rees J, Patel B, MacDonagh R, Persad R. Cryosurgery for prostate cancer. BJU Int 2004; 93(6): 710–714.
Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 1995; 55(15): 3346–3351.
Bozzini G, Colin P, Nevoux P, Villers A, Mordon S, et al. Focal therapy of prostate cancer: Energies and procedures. Ural Oncol-Semin Ori 2013; 31(2): 155–167. doi: 10.1016/j.urolonc.2012.05.011.
Langley S, Ahmed H, Al-Qaisieh B, Bostwick D, Dickinson L, et al. Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. BJU Int 2012; 109: 7–16. doi: 10.1111/j.1464-410X.2011.10825.x.
Cosset J-M, Cathelineau X, Wakil G, Pierrat N, Quenzer O, et al. Focal brachytherapy for selected low-risk prostate cancers: A pilot study. Brachytherapy 2013; 12(4): 331–337. doi: 10.1016/j.brachy.2013.02.002.
Nguyen P, Chen MH, Zhang Y, Tempany CM, Cormack RA, et al. Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: Implications for focal therapy. J Urology 2012; 188(4): 1151–1156. doi: 10.1016/j.juro.2012.06.010.
Kamrava M, Chung M, Kayode O, Wang J, Marks L, et al. Focal high-dose-rate brachytherapy: A dosimetric comparison of hemigland vs. conventional whole-gland treatment. Brachytherapy 2013; 12(5): 434–441. doi: 10.1016/j.brachy.2012.09.002.
Mason J, Al-Qaisieh B, Bownes P, Thwaites D, Henry A. Dosimetry modeling for focal high-dose-rate prostate brachytherapy. Brachytherapy 2014; 13(6): 611–617. doi: 10.1016/j.brachy.2014.06.007.
Morris W. Focal therapy for prostate cancer: A pilot study of focal low dose rate brachytherapy (FTPC) [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT01830166.
Downs S, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Commun H 1998; 52(6): 377–348. doi: 10.1136/jech.52.6.377.
Rischmann P, Hoquetis L, Crouzet S, Pasticier G, Villers A, et al. 358 Focal therapy with HIFU for localized prostate cancer: A prospective multicentric study. Eur Urol Supplements 2014; 13(1): e358. doi: 10.1016/S1569-9056(14)60353-5.
Mendez M, Passoni N, Pow-Sang J, Jones S, Polasick T. Comparison of outcomes between preoperatively potent men treated with focal versus whole gland cryotherapy in a matched population. J Endourol 2015; 29(10): 1193–1198. doi: 10.1089/end.2014.0881.
Feijoo E, Sivaraman A, Barret E, Sanchez-Salas R, Galiano M, et al. Focal high-intensity focused ultrasound targeted hemiablation for unilateral prostate cancer: A prospective evaluation of oncologic and functional outcomes. Eur Urol 2016; 69(2): 214–220. doi: 10.1016/j.eururo.2015.06.018.
Van Velthoven R, Aoun F, Limani K, Narahari K, Lemort M, et al. Primary zonal high intensity focused ultrasound for prostate cancer: Results of a prospective phase IIa feasibility study. Prostate Cancer 2014; 2014: 756189. doi: 10.1155/2014/756189.
Hale Z, Miyake M, Palacios DA, Rosser CJ. Focal cryosurgical ablation of the prostate: A single institute’s perspective. BMC Urol 2013; 13(1): 1–6. doi: 10.1186/1471-2490-13-39.
Dickinson L, Ahmed HU, Kirkham AP, Allen C, Freeman A, et al. A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: The INDEX study. Contemp Clin Trials 2013; 36(1): 68–80. doi: 10.1016/j.cct.2013.06.005.
Ward J, Jones J. Focal cryotherapy for localized prostate cancer: A report from the national Cryo On-Line Database (COLD) Registry. BJU Int. 2012; 109(11): 1648–1654. doi: 10.1111/j.1464-410X.2011.10578.x.
Truesdale M, Cheetham P, Hruby G Wenske S, Conforto A, et al. An evaluation of patient selection criteria on predicting progression-free survival after primary focal unilateral nerve-sparing cryoablation for prostate cancer: Recommendations for follow up. Cancer J 2010; 16(5): 544–549. doi: 10.1097/PPO.0b013e3181f84639.
Ellis D, Manny Jr T, Rewcastle J. Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: Initial results. Urology 2007; 70(6): 9–15. doi: 10.1016/j.urology.2007.07.036.
Lambert E, Bolte K, Masson P, Katz A. Focal cryosurgery: Encouraging health outcomes for unifocal prostate cancer. Urology 2007; 69(6): 1117–1120. doi: 10.1016/j.urology.2007.02.047.
Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J. “Male Lumpectomy”: Focal therapy for prostate cancer using cryoablation. Urology 2007; 70(6): S16–S21. doi: 10.1016/j.urology.2007.06.001.
Bahn D, Silverman P, Lee F, Badalament R, Bahn E, Rewcastle J. Focal prostate cryoablation: Initial results show cancer control and potency preservation. J Endourol 2006; 20(9): 688–692. doi: 10.1089/end.2006.20.688.
Ghai S, Louis A, Van Vliet M Lindner U, Haider M, et al. Real-time MRI-guided focused ultrasound for focal therapy of locally confined low-risk prostate cancer: Feasibility and preliminary outcomes. Am J Roentgenol 2015; 205(2): 177–84. doi: 10.2214/AJR.14.13098.
Gelet A, Crouzet S, Rouviere O, Bratan F, Chapelon JY. Focal treatment of prostate cancer using focal one device: Pilot study results. J Therapeutic Ultrasound 2015; 3: O54–O54. doi: 10.1186/2050-5736-3-S1-O54.
Ahmed H, Dickinson L, Charman S Weir S, McCartan N et al., Focal ablation targeted to the index lesion in multifocal localised prostate cancer: A prospective development study. Eur Urol 2015; 68(6): 927–936. doi: 10.1016/j.eururo.2015.01.030.
Del Monte M, Napoli A, Anzidei M, Cartocci G, Caliolo G, et al. Non-invasive focal therapy of organ confined prostate cancer: Phase I study using MrgFus and excision pathology for efficacy assessment. EPOS 2015. doi: 10.1594/ecr2015/C-1899.
Barqawi A, Stoimenova D, Krughoff K, Eid K, O’Donnell C, et al. Targeted focal therapy for the management of organ confined prostate cancer. J Urology 2014; 192(3): 749–753. doi: 10.1016/j.juro.2014.03.033.
Durand M, Barret E, Galiano M, Rozet F, Sanchez-Salas R, et al. Focal cryoablation: A treatment option for unilateral low-risk prostate cancer. BJU Int 2014; 113(1): 56–64. doi: 10.1111/bju.12370.
Bahn D, de Castro Abreu AL, Gill I, Inderbir S, Hung A, et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol 2012; 62(1): 55–63. doi: 10.1016/j.eururo.2012.03.006.
Lindner U, Weersink RA, Haider MA, Gertner MR, Davidson SR, et al. Image guided photothermal focal therapy for localized prostate cancer: Phase I trial. J Urol 2009; 182(4): 1371–1377. doi: 10.1016/j.juro.2009.06.035.
Ahmed H, Hindley R, Dickinson L, Freeman A, Kirkham A, et al. Focal therapy for localised unifocal and multifocal prostate cancer: A prospective development study. Lancet Oncol 2012; 13(6): 622–632. doi: 10.1016/S1470-2045(12)70121-3.
Dickinson L, Ahmed H, McCartan N, Freeman A, Kirkham A, et al. Medium term outcomes following primary focal therapy using HIFU for localised prostate cancer. BJU Int 2012; 109(S7): 6.
Ahmed H, Freeman A, Kirkman A, Sahu M, Scott R, et al. Focal therapy for localized prostate cancer: A phase I/II trial. J Urology 2011; 185(4): 1246–1255. doi: 10.1016/j.juro.2010.11.079.
Mendez M, Passoni N, Pow-Sang J, Jones J, Polascik T. Comparison of outcomes between preoperatively potent men treated with focal versus whole gland cryotherapy in a matched population. J Endourol 2015; 29(10): 1193–1198. doi: 10.1089/end.2014.0881.
Napoli A, Anzidei M, De Nunzio C, Cartocci G, Panebianco V, et al. Real-time magnetic resonance-guided high-intensity focused ultrasound focal therapy for localised prostate cancer: Preliminary experience. Eur Urol 2013; 63(2): 395–398. doi: 10.1016/j.eururo.2012.11.002.
Chopra R, Colquhoun A, Burtnyk M, N’djin W, Kobelevskiy I, et al. MR imaging–controlled transurethral ultrasound therapy for conformal treatment of prostate tissue: Initial feasibility in humans. Radiology 2012; 265(1): 303–313. doi: 10.1148/radiol.12112263.
Tareen B, Godoy G, Taneja SS. Focal therapy: A new paradigm for the treatment of prostate cancer. Rev Urol 2009; 11(4): 203–212. doi: 10.3909/riu0475.
Klotz L, Zhang L, Lam A, Nam R, Mamedov A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28(1): 126–131. doi: 10.1016/j.eururo.2010.04.015.
Ahmed H, Pendse D, Illing R, Allen C, van der Meulen J, et al. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Prac Oncol 2007; 4(11): 632–642. doi: 10.1038/ncponc0959.
van den Bergh R, Essink-Bot M, Roobol M, Wolters T, Shroder F, et al. Anxiety and distress during active surveillance for early prostate cancer. Cancer 2009; 115(17): 3868–3878. doi: 10.1002/cncr.24446.
Harlan S, Cooperberg M, Elkin E Lubeck D, Meng M, et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: Results from CaPSURE. J Urol 2003; 170(5): 1804–1807. doi: 10.1097/01.ju.0000091641.34674.11.
Stephenson A, Kattan M, Eastham J, Bianco F, Yossepowitch O, et al. Prostate cancer – Specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009; 27(26): 4300–4305. doi: 10.1200/JCO.2008.18.2501.
Alicikus Z, Yamada Y, Zhang Z, Pei X, Hunt M, et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 2011; 117(7): 1429–1437. doi: 10.1002/cncr.25467.
Sylvester J, Grimm P, Wong J, Galbreath R, Merrick G, et al. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I125 prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Rad Oncol Biol Phys 2011; 81(2): 376–381. doi: 10.1016/j.ijrobp.2010.05.042.
Wilt T, Brawer M. The prostate cancer intervention versus observation trial: A randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol 1994; 152(5): 1910–1914. doi: 10.1016/S0022-5347(17)32413-8.
Gore J, Kwan L, Lee S, Reiter R, Litwin M. Survivorship beyond convalescence: 48-Month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst 2009; 101(12): 888–892. doi: 10.1093/jnci/djp114.
Rice K, Hudak J, Peay K, Elsamanoudi S, Travis J, et al. Comprehensive quality-of-life outcomes in the setting of a multidisciplinary, equal access prostate cancer clinic. Urology 2010; 76(5): 1231–1238. doi: 10.1016/j.urology.2010.03.087.
Huang G, Sadetsky N, Penson D. Health related quality of life for men treated for localized prostate cancer with long-term followup. J Urol 2010; 183(6): 2206–2212. doi: 10.1016/j.juro.2010.02.013.
Pardo Y, Gueda F, Aguilo F, Ferran F, Macias V, et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol 2010; 28: 4687–4696. doi: 10.1200/JCO.2009.25.3245.
Humphrey P. Complete histologic serial sectioning of a prostate gland with adenocarcinoma. Am J Surg Pathol 1993; 17(5): 468–472.doi: 10.1097/00000478-199305000-00005.
Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009; 15(5): 559–565. doi: 10.1038/nm.1944.
Haffner M, Mosbruger T, Esopi D, Fedor H, Heaphy C, et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest 2013; 123(11): 4918–4922. doi: 10.1172/JCI70354.
Giannarini G, Gangaglia G, Montorsi F, Briganti A. Will focal therapy remain only an attractive illusion for the primary treatment of prostate cancer? J Clin Oncol 2014; 32(13): 1299–1301. doi: 10.1200/JCO.2013.54.8214.
Fütterer J, Briganti A, De Visschere P, Emberton M, Giannarini G, et al. Can clinically significant prostate cancer be dpetected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol 2015; 68(6): 1045–1053.
Le J, Tan N, Shkolyar E, Lu D, Kwan L, et al. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: Correlation with whole-mount histopathology. Eur Urol 2015; 67(3): 569–576. doi: 10.1016/j.eururo.2014.08.079.
Muller BG, van den Bos W, Brausi M, Futterer J, Ghai S, et al. Follow-up modalities in focal therapy for prostate cancer: Results from a Delphi consensus project. World J Urol 2015; 33(10): 1503–1509. doi: 10.1007/s00345-014-1475-2.
Ahmed H, Akin O, Coleman J, Crane S, Emberton M, et al. Transatlantic consensus group on active surveillance and focal therapy for prostate cancer. BJU Int 2012; 109(11): 1636–1647. doi: 10.1111/j.1464-410X.2011.10633.x.
Taira A, Merrick G, Galbreath R, Andreini H, Taubenslag W, et al. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer P D 2010 13(1): 71–77. doi: 10.1038/pcan.2009.42.
Ahmed H, Hu Y, Carter T, Arumainayagam N, Lecornet E, et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urology 2011; 186(2): 458–464. doi: 10.1016/j.juro.2011.03.147.
Ward JF III, Rewcastle J, Ukimura O, Gill I. Focal therapy for the treatment of localized prostate cancer: A potential therapeutic paradigm shift awaiting better imaging. Curr Opin Urol 2012; 22(2): 104–108. doi: 10.1097/MOU.0b013e3283501813.
Buskirk S, Pinkstaff D, Petrou S, Wehle M, Broderick G, et al. Acute urinary retention after transperineal template-guided prostate biopsy. Int J Rad Oncol Biol Phys 2004; 59(5): 1360–1366. doi: 10.1016/j.ijrobp.2004.01.045.
Eggener S, Scardino P, Carroll P, Zelefsky M, Sartor O, et al. Focal therapy for localized prostate cancer: A critical appraisal of rationale and modalities. J Urology 2007; 178(6): 2260–2267. doi: 10.1016/j.juro.2007.08.072.
Dickinson L, Ahmed HU, Allen C, Barentsz J, Carey B, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: Recommendations from a European consensus meeting. Eur Urol 2011; 59(4): 477–494. doi: 10.1016/j.eururo.2010.12.009.
Bantema-Joppe E, de Munck L, Visser O, Willemse P, Langendijk J, et al. Early-stage young breast cancer patients: Impact of local treatment on survival. Int J Rad Oncol Biol Phys 2011; 81(4): e553–e559. doi: 10.1016/j.ijrobp.2011.02.060.
Valerio M, Ahmed H, Emberton M, Lawrenstschuk N, Lazzeri M, et al. The role of focal therapy in the management of localised prostate cancer: A systematic review. Eur Urol 2014; 66(4): 732–751. doi: 10.1016/j.eururo.2013.05.048.
Gradishar W, Anderson B, Balassanian R, Blair S, Burnstein H, et al. Invasive breast cancer version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2016; 14(3): 324–354. doi: 10.6004/jnccn.2016.0037.
Veronesi U, Luini A, Del Vecchio M, Greco M, Galimberti V, et al. Radiotherapy after breast preserving surgery in women with localised cancer of the breast. N Eng J Med 1992; 328(22): 1587–1591. doi: 10.1056/NEJM199306033282202.
Peeters S, Heemsbergen W, Koper P, van Putten W, Slot A, et al. Dose-response in radiotherapy for localized
prostate cancer: Results of the dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006; 24(13): 1990–1996. doi: 10.1200/JCO.2005.05.2530.
Mouraviev V, Nosnik I, Sun L, Robertson C, Walther P, et al. Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: A single-institution experience. Urology 2007; 69(2): 311–314. doi: 10.1016/j.urology.2006.10.025.
Bortfeld T, Marks L. Hype cycle in radiation oncology. Int J Rad Oncol Biol Phys 2013; 86(5): 819–821. doi: 10.1016/j.ijrobp.2013.03.027.
Novara G, Ficarra V, Rosen R, Artibani W, Costello A, et al. Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol 2012; 62(3): 431–452. doi: 10.1016/j.eururo.2012.05.044.
McCulloch P. The IDEAL recommendations and urological innovation. World J Urol 2011; 29(3): 331–336. doi: 10.1007/s00345-011-0647-6.
DOI: http://dx.doi.org/10.30564/amor.v3i6.141
Refbacks
- There are currently no refbacks.
Copyright (c) 2018 Aisling Glynn, Elizabeth Forde, Laure Marignol

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.